Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
IMRX

IMRX - Immuneering Corporation Stock Price, Fair Value and News

$5.05-0.40 (-7.34%)
Market Closed

34/100

IMRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

34/100

IMRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

IMRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMRX Price Action

Last 7 days

-5.2%

Last 90 days

-16.9%

Trailing 12 Months

227.9%

IMRX RSI Chart

IMRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMRX Valuation

Market Cap

222.3M

Price/Earnings (Trailing)

-3.97

Price/Sales (Trailing)

740.12

EV/EBITDA

-2.11

Price/Free Cashflow

-4.89

IMRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

IMRX Fundamentals

IMRX Revenue

Revenue (TTM)

317.0K

IMRX Earnings

Earnings (TTM)

-56.0M

Earnings Growth (Yr)

35.85%

Earnings Growth (Qtr)

22.62%

IMRX Profitability

Operating Margin

100.00%

EBT Margin

-15937.29%

Return on Equity

-25.64%

Return on Assets

-24.15%

Free Cashflow Yield

-20.47%

IMRX Investor Care

Shares Dilution (1Y)

46.80%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20221.5M949.8K506.1K317.0K
20212.3M2.2M2.1M2.1M
20200002.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About Immuneering Corporation

IMRX
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://immuneering.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES66

Immuneering Corporation Frequently Asked Questions

IMRX is the stock ticker symbol of Immuneering Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Immuneering Corporation is 222.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, IMRX's PE ratio (Price to Earnings) is -3.97 and Price to Sales (PS) ratio is 740.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMRX PE ratio will change depending on the future growth rate expectations of investors.